Financial Contrast: ADB International Group (OTCMKTS:EQUR) and Atossa Genetics (NASDAQ:ATOS)

Atossa Genetics (NASDAQ:ATOS) and ADB International Group (OTCMKTS:EQUR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Profitability

This table compares Atossa Genetics and ADB International Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-49.42%	-44.76%
ADB International Group	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings for Atossa Genetics and ADB International Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2	0	2	1	2.40
ADB International Group	0	0	0	0	0.00

Atossa Genetics currently has a consensus price target of $95.00, suggesting a potential upside of 2,088.94%. Given Atossa Genetics’ stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than ADB International Group.

Insider and Institutional Ownership

12.7% of Atossa Genetics shares are owned by institutional investors. 9.5% of Atossa Genetics shares are owned by insiders. Comparatively, 79.6% of ADB International Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Atossa Genetics and ADB International Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$25.50 million	($3.60)	-1.21
ADB International Group	N/A	N/A	N/A	N/A	N/A

Summary

Atossa Genetics beats ADB International Group on 5 of the 8 factors compared between the two stocks.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

About ADB International Group

E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices. Its BST devices implement patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The company was incorporated in 1988 and is based in New York, New York.